All News

uveitis.3.jpg

Risk of Uveitis with Spondyloarthritis

d Jack Cush, MD

A retrospective registry study shows that uveitis may be seen in 10% with the diagnosis of axial spondyloarthritis (axSpA) but becomes more common (47%) over the next 30 years of disease. The good news is that biologic therapy can significantly lower the risk of uveitis in (SpA).

Read Article
capsules,antibiotic

Long Term Antibiotics Increase Risk of RA

d Jack Cush, MD

JAMA has published a population-based retrospective cohort study showing a possible association between the long-term use of antibiotics and the risk of rheumatoid arthritis (RA).

Read Article
low res disease image

Hand-Held Imaging Could Transform Arthritis Care

d EurekAlert!

A new hand-held scanner developed by UCL researchers can generate highly detailed 3D photoacoustic images in just seconds, paving the way for their use in a clinical setting for the first time and offering the potential for earlier disease diagnosis.

Read Article
Fatigue, FM, fibromyalgia

2023 EULAR Recommendations on Management of Fatigue

d Jack Cush, MD

A 2023 EULAR task force has made recommendations to the approach and management of fatigue in patients with inflammatory rheumatic and musculoskeletal diseases (I-RMDs).

Read Article
MRI.knee_.jpg

Using MRI to Evaluate Knee Pain

d MedPage Today

Interim results from a randomized trial show that middle-aged patients with knee pain and suspected meniscal tears can benefit from MRI scans even in relatively simple cases.

Read Article
xray%20spine%20films_0.jpg

ASAS Imaging Recommendations for Suspected Spondyloarthritis

d Jack Cush, MD

ASAS (Assessment of Spondyloarthritis International Society) has convened specialized task force to guide imaging request on patients with suspected/known axial spondyloarthritis (axSpA).

Read Article
Using MRI to Evaluate Knee Pain Interim results from a randomized trial show that middle-aged patients with knee pain and suspected meniscal tears can benefit from MRI scans even in relatively simple cases. https://t.co/xAVA07LcqD https://t.co/YRrZgiMQjs

Links:

Dr. John Cush RheumNow ( View Tweet)
A randomized, controlled study of whole-body electromyostimulation (strength training) in 72 overweight symptomatic knee OA pts Rx w/ usual care vs WB-EMS (3x q 14d) for 7 mos. WB-EMS had signif improved knee pain (KOOS),(-9.0 points, p 0.004) & function https://t.co/UWs3YgYB9F https://t.co/odwsd4AuCh

Links:

Dr. John Cush RheumNow ( View Tweet)
Medical Expenditure Panel Survey study (2018 to 2020) identified 4.27 million adults with RA and found significantly higher (mean $3,382) health care expenditures, particularly prescription medication costs, and was associated with suboptimal quality of life… https://t.co/87os1PWT2F https://t.co/znmkucBIdE
Dr. John Cush RheumNow ( View Tweet)
Taiwan claims data study compared (2003-2013) 30,911 newly diagnosed #AS pts to 309,110 controls found significantly higher risk of motor vehicle accidents w/ injuries in AS, esp. 2yrs after Dx (IRR 2.0) https://t.co/Ca0LN675oj https://t.co/UKQMgQYMAL

Links:

Dr. John Cush RheumNow ( View Tweet)
Study of oral microbiota & psoriasis (72 PSO vs 16 healthy controls) - 16S rRNA gene sequencing of saliva found (in PSO) signif incrCapnocytandophaga, Campylobacter, Acetobacter, but decr Bacteroides, Muribaculaceae. PSA pts incr Aggregatibacter, but decr Prevotella… https://t.co/GukbWkl1Gz https://t.co/HgLcD6bP2I
Dr. John Cush RheumNow ( View Tweet)
Declining Menopausal Hormone Therapy in Postmenopausal Women A two decade cross-sectional population study has shown a marked downward trend in menopausal hormone therapy (MHT), with an over 80% reduction, especially in women aged 52 - 65 years. https://t.co/yKPGTOAFvQ https://t.co/72etpOVrSO

Links:

Dr. John Cush RheumNow ( View Tweet)
Have a a rheumatology question or case for Jack Cush? Record it here and we may feature it on an upcoming podcast. Tell us your name and where you practice rheumatology. https://t.co/wvZYVbVW83 https://t.co/n26xAeU64s

Links:

Dr. John Cush RheumNow ( View Tweet)
Trends in Early Undifferentiated PolyArthritis presentation. Over 3 eras (1998-2004-245 pts; 2005-10 266 pts; 2011-22 329 pts) many Sxs & Rx same. But Sxs duration 2.9 to 4.1mos, seropositivity 54 to 42%, Erosion score 18 to 9, mostly in Seroneg pts; Steroids incr 18 to 33%… https://t.co/AZfjqB4xGI https://t.co/GEwDWjccxl
Dr. John Cush RheumNow ( View Tweet)
Which One is the Loneliest Number (9.27.2024) Dr. Jack Cush reviews the regulatory approvals, announcements, guidelines and interesting journal articles from the past week on RheumNow. When not to use muscle relaxants, how frequent is loneliness in RA/PsA/SpA, and when to refer… https://t.co/c4YKKXbweX https://t.co/pEaA5qVvd9
Dr. John Cush RheumNow ( View Tweet)

CORRECTION!! UCB announced the LAUNCH of a new phase 3b BE BOLD trial - this study has no report results as yet. It WILL BE a H2H RCTcomparing bimekizumab & rizankizumab in adult #PsA pts using an ACR50 primary endpoint. Yesterday we incorrectly reported this as a completed… https://t.co/apa6VMuQTi https://t.co/BTpwo6ww7W

Dr. John Cush RheumNow ( View Tweet)
Full read review and metanalysis of 11 articles shows nearly 60% of #RA demonstrate an elevated Coronary Artery Calcification (CAC) score; RA pts have higher CAC scores (&CV risk) than their healthy counterparts. https://t.co/aWE2Ul6WDu https://t.co/QHFbRzytTZ

Links:

Dr. John Cush RheumNow ( View Tweet)
NOR-Gout study shows Non-adherence to urate lowering therapy after 5 years is related to poor gout outcomes. 5-year Observational study of 163 patients showed overall good ULT adherence but nonadherent had more flares (33 vs 10%) & less at target (45 vs 87%)… https://t.co/xuIjBiuFHF https://t.co/fmqkCOYayP
Dr. John Cush RheumNow ( View Tweet)
Stratified Cancer Screening in Dermatomyositis The International Myositis Assessment and Clinical Studies Group (IMACS) have published evidence and consensus based cancer screening guidelines for patients with idiopathic inflammatory myopathies, including dermatomyositis.… https://t.co/IQ8JpUMtnn https://t.co/eEM2uuQbKB
Dr. John Cush RheumNow ( View Tweet)
UCB released topline results of a phase 3b H2H "BE BOLD" RCT of bimekizumab (anti-IL17) vs rizankizumab (anti-IL23) in 550 active adult #PsA pts - at wk 16 inhibition of IL-17A/F was superior to IL-23 using the ACR50 primary endpoint. https://t.co/aWnHYefS2C https://t.co/2Vft5fouFv

Links:

Dr. John Cush RheumNow ( View Tweet)
×